Photocure Provides Update on AssureMDx and Anticipated Medicare Coverage Timeline

Impact · against what's priced in

Photocure's stock is moderately positive as indications of higher-than-expected reimbursement per test outweigh the failure to achieve accelerated Medicare coverage. The lack of inclusion in the Novitas LCD simply returns the timeline to the original 2028 target, while the pending year-end pricing determination provides a concrete floor for 2027 revenue models.

PHO+0.30

No priced-in read yet